Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ · Entity 2722 | Director | April 23, 2026 | April 27, 2026 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | August 13, 2026 | August 17, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 05, 2020 | May 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JOHNSON & JOHNSON
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 5,359.3973 |
Reported balance
After 2026-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-23 · Grant · Acquired 975 · Balance 5,359.3973 F1: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date).
F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.
Maze Therapeutics, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.67 · Expires 2036-08-12 | Direct | 36,000 |
Reported balance
After 2026-08-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-13 · Grant · Acquired 36,000 · Balance 36,000 F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
WEST PHARMACEUTICAL SERVICES INC
Report date May 05, 2020 · Filed May 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,753.6715 |
Reported balance
After 2020-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 975 · Balance 48,753.6715 F1: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
F2: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABIOMED INC
Report date December 22, 2022 · Filed December 27, 2022
Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 1
1 source rowRow 1 · 2022-12-22 · Disposition to issuer · Disposed 1,659 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.
Mirror Merger Sub 2, LLC
Report date March 01, 2021 · Filed March 03, 2021
Section 16 reporting ended · disclosed 2021-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-01 · Disposition to issuer · Disposed 5,840 · Balance 0 F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F2: This Deferred Stock Unit award was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $426,320.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock.
F2: This Deferred Stock Unit award was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $426,320.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 17, 2026 20:51 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $27.67 | $0.00 |
DisclosureSEC source: 0001341161-26-000005 · form4-08172026_080804.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:01 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000098 · wk-form4_1777327261.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,359.3973 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 24, 2025 Filed Apr 28, 2025 21:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,316 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000127 · wk-form4_1745876716.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,265.9823 Underlying: Common Stock · 1,316 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 21:05 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,385.697 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005329 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,858.548 Underlying: Common Stock · 1,385.697 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| August 23, 2023 Filed Jan 28, 2026 23:29 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Disposition to issuerCommon Stock | 11 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000006 · wk-form5_1769642965.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89 F1 · price: On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer. Read SEC document |
| April 27, 2023 Filed May 2, 2023 21:21 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,429.5 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005252 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429.5 Underlying: Common Stock · 1,429.5 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:29 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerCommon Stock, $.01 par value | 1,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-013007 · form4-12272022_101206.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · kind: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F1 · shares: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · shares: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 16:02 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock, $.01 par value | 263 | $293.34 | $77,148.42 |
DisclosureSEC source: 0001415889-22-008523 · form4-08122022_010800.xml · nonDerivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,659 F2 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F2 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 16:02 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock, $.01 par value | 681 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008523 · form4-08122022_010800.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,922 F1 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) the first anniversary of the date of grant; and (b) the date of the Corporation's 2023 Annual Meeting; that such awards shall be subject to a Time-Based Restricted Stock Unit Award Agreement in accordance with the Second Amended & Restated 2015 Omnibus Incentive Plan. F1 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) the first anniversary of the date of grant; and (b) the date of the Corporation's 2023 Annual Meeting; that such awards shall be subject to a Time-Based Restricted Stock Unit Award Agreement in accordance with the Second Amended & Restated 2015 Omnibus Incentive Plan. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 16:04 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 101 | $302.14 | $30,516.14 |
DisclosureSEC source: 0001415889-22-004360 · form4-04292022_010420.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 16:20 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008173 · edgar.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342 F1 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a)August 11, 2022; or (b) the date of the Issuer's next annual meeting of stockholders. F1 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a)August 11, 2022; or (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 16:41 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004649 · edgar.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717 F1 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of April 26, 2022, April 26, 2023 and April 26, 2024. F1 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of April 26, 2022, April 26, 2023 and April 26, 2024. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:25 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Disposition to issuerDeferred Stock · Derivative | 5,840 | $73.00 Strike: $0.00 | $426,320.00 |
DisclosureSEC source: 0001225208-21-004545 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Eaton Vance Corp. Non-voting Common Stock · 5,840 shares Expires not disclosed F1 · security: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F2 · price: This Deferred Stock Unit award was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $426,320.00. F2 · derivative.exercise_date: This Deferred Stock Unit award was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $426,320.00. F2 · derivative.expiration_date: This Deferred Stock Unit award was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $426,320.00. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 17:33 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 31 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002530 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,840 Underlying: Eaton Vance Corp. Non-voting Common Stock · 31 shares Expires not disclosed F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. F3 · derivative.exercise_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. F3 · derivative.expiration_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| December 18, 2020 Filed Dec 18, 2020 13:48 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 347 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-014874 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,809 Underlying: Eaton Vance Corp. Non-voting Common Stock · 347 shares Expires not disclosed F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. F3 · derivative.exercise_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. F3 · derivative.expiration_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 14:34 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 20 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-013580 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,462 Underlying: Eaton Vance Corp. Non-voting Common Stock · 20 shares Expires not disclosed F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. F3 · derivative.exercise_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. F3 · derivative.expiration_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 16:00 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 2,317 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-013013 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,442 Underlying: Eaton Vance Corp. Non-voting Common Stock · 2,317 shares Expires not disclosed F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · derivative.exercise_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. F2 · derivative.expiration_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 17:05 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionDeferred Stock · Derivative | 3,303 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012964 · doc4.xml · derivative · entry 4 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Eaton Vance Corp. Non-voting Common Stock · 3,303 shares Expires 2020-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 17:05 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 20 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012964 · doc4.xml · derivative · entry 3 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,303 Underlying: Eaton Vance Corp. Non-voting Common Stock · 20 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 17:05 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Disposition to issuerEaton Vance Corp. Non-voting Common Stock | 3,303 | $59.79 | $197,486.37 |
DisclosureSEC source: 0001225208-20-012964 · doc4.xml · nonDerivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 17:05 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionEaton Vance Corp. Non-voting Common Stock | 3,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012964 · doc4.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2020 Filed Oct 27, 2020 15:58 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionDeferred Stock · Derivative | 3,563 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012768 · doc4.xml · derivative · entry 3 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Eaton Vance Corp. Non-voting Common Stock · 3,563 shares Expires 2020-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. Read SEC document |
| October 24, 2020 Filed Oct 27, 2020 15:58 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Disposition to issuerEaton Vance Corp. Non-voting Common Stock | 3,563 | $62.06 | $221,119.78 |
DisclosureSEC source: 0001225208-20-012768 · doc4.xml · nonDerivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 24, 2020 Filed Oct 27, 2020 15:58 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionEaton Vance Corp. Non-voting Common Stock | 3,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012768 · doc4.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 16:08 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 32 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-010635 · doc4.xml · derivative · entry 3 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,283 Underlying: Eaton Vance Corp. Non-voting Common Stock · 32 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 16:08 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 35 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-010635 · doc4.xml · derivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,563 Underlying: Eaton Vance Corp. Non-voting Common Stock · 35 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 16:08 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 31 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-010635 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Eaton Vance Corp. Non-voting Common Stock · 31 shares Expires not disclosed F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. F3 · derivative.exercise_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. F3 · derivative.expiration_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| May 15, 2020 Filed May 15, 2020 14:24 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 37 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007782 · doc4.xml · derivative · entry 3 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,251 Underlying: Eaton Vance Corp. Non-voting Common Stock · 37 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| May 15, 2020 Filed May 15, 2020 14:24 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 40 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007782 · doc4.xml · derivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,528 Underlying: Eaton Vance Corp. Non-voting Common Stock · 40 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| May 15, 2020 Filed May 15, 2020 14:24 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 35 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007782 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,094 Underlying: Eaton Vance Corp. Non-voting Common Stock · 35 shares Expires not disclosed F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. F3 · derivative.exercise_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. F3 · derivative.expiration_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:05 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-003463 · primarydocument.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,753.6715 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| February 14, 2020 Filed Feb 14, 2020 16:54 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 26 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002395 · doc4.xml · derivative · entry 3 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,214 Underlying: Eaton Vance Corp. Non-voting Common Stock · 26 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| February 14, 2020 Filed Feb 14, 2020 16:54 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 28 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002395 · doc4.xml · derivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,488 Underlying: Eaton Vance Corp. Non-voting Common Stock · 28 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| February 14, 2020 Filed Feb 14, 2020 16:54 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 25 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002395 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,059 Underlying: Eaton Vance Corp. Non-voting Common Stock · 25 shares Expires not disclosed F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. F3 · derivative.exercise_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. F3 · derivative.expiration_date: Shares of Deferred Stock become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 15:26 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 28 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-014538 · doc4.xml · derivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,188 Underlying: Eaton Vance Corp. Non-voting Common Stock · 28 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 15:26 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 31 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-014538 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,460 Underlying: Eaton Vance Corp. Non-voting Common Stock · 31 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 16:53 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 3,034 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-014056 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,034 Underlying: Eaton Vance Corp. Non-voting Common Stock · 3,034 shares Expires not disclosed F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · derivative.exercise_date: The shares of Deferred Stock granted on November 1, 2019 become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. F2 · derivative.expiration_date: The shares of Deferred Stock granted on November 1, 2019 become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 15:33 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 26 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-011441 · doc4.xml · derivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,160 Underlying: Eaton Vance Corp. Non-voting Common Stock · 26 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. F3 · derivative.expiration_date: The shares of Deferred Stock granted on November 1, 2018 become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 15:33 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 28 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-011441 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,429 Underlying: Eaton Vance Corp. Non-voting Common Stock · 28 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| May 15, 2019 Filed May 15, 2019 13:37 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 27 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008039 · doc4.xml · derivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,134 Underlying: Eaton Vance Corp. Non-voting Common Stock · 27 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. F3 · derivative.expiration_date: The shares of Deferred Stock granted on November 1, 2018 become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| May 15, 2019 Filed May 15, 2019 13:37 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 29 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008039 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,401 Underlying: Eaton Vance Corp. Non-voting Common Stock · 29 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| May 07, 2019 Filed May 9, 2019 19:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-002733 · primarydocument.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,967.0171 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 15:59 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 30 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002745 · doc4.xml · derivative · entry 2 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,107 Underlying: Eaton Vance Corp. Non-voting Common Stock · 30 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 15:59 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 32 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002745 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,372 Underlying: Eaton Vance Corp. Non-voting Common Stock · 32 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 13:15 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 25 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015580 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,340 Underlying: Eaton Vance Corp. Non-voting Common Stock · 25 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Deferred Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Deferred Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 17:14 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 3,077 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015186 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,077 Underlying: Eaton Vance Corp. Non-voting Common Stock · 3,077 shares Expires 2020-11-01 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. F2 · derivative.expiration_date: The shares of Deferred Stock granted on November 1, 2018 become payable in cash based on the non-employee director's election at either (1) the earlier of the second anniversary of the grant date or the date of the non-employee director's termination, or (2) upon the non-employee director's termination. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 08:56 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantDeferred Stock · Derivative | 3,315 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-014878 · doc4.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,315 Underlying: Eaton Vance Corp. Non-voting Common Stock · 3,315 shares Expires 2020-10-24 F1 · security: Each share of Deferred Stock is the economic equivalent of one share of non-voting common stock. Read SEC document |
| May 01, 2018 Filed May 3, 2018 21:47 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002198 · primarydocument.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,402.0171 F1 · price: These shares of restricted stock units will vest in full on the first anniversay of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 15, 2017 Filed Jan 9, 2018 18:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Disposition to issuerCommon Stock | 2,275 | $98.98 | $225,179.50 |
DisclosureSEC source: 0001562180-18-000266 · primarydocument.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,578.0171 Read SEC document |
| May 02, 2017 Filed May 3, 2017 18:55 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001687 · primarydocument.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,853.0171 F1 · price: These shares of restricted stock units will vest in full after 12 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.